You are absolutely right. The only one who is infatuated with numbers in charty. In the real world, analysts and investors are interested in only one thing, success stories, not the number of drugs in the pipeline unless they turn out to be successful. As far as PFE is concerned, analysts and investors have been disappointed too many times with 'sure bets' that have turned out to be stupendous flops such as Torcetrabib and Exubera. Plain and simple, it is 'put up or shut up' time for PFE. Quoting the increased numbers of drugs in the pipeline is not going to do anything positive.